

NEOVACS Main publications

(2004) Zagury D & R.C. Gallo: Anti-cytokine Ab immune therapy: present status and perspectives. *DDT* 9:72-81.

(2003) Zagury D., Le Buanec H., Bizzini B., Burny A., Lewis G. & R.C. Gallo: Active versus passive anti-cytokine antibody therapy against cytokine-associated chronic diseases. *Cytokine and Growth factor Reviews* 247:1-15.

(2003) Le Buanec H., Cohen L., Paturance S., Burny A., Gallo R.C. & D. Zagury: Therapeutic vaccine to control stromal tumor-induced immunosuppression in human uterine cervix cancer. *Cellular & Molecular Biology* 49:667-671.

(2002) Le Buanec H., Bizzini B., Burny A., Gallo R.C. & D. Zagury: Vaccine to combat immunosuppressive stroma-derived factor in uterine cervix cancer. *Progression therapy and prevention. Proceeding of the 2nd Int. conf. on tumor microenvironment*. Baden Austria 207-211.

(2002) Gallo R.C., Burny A. & D. Zagury: Targeting Tat and IFN α as a therapeutic AIDS vaccine. *DNA and Cell Biology* 21:611-618.

(2001) Zagury D., Le Buanec H., Bizzini B. & R.C. Gallo: Non-toxic immunogens for therapeutic anticytokine vaccines. *Idrugs* 4:1161-1166.

(2001) Zagury D., Burny A. & R.C. Gallo: Towards a new generation of vaccines: the anti-cytokine therapeutic vaccines. *Proc. Natl. Acad. Sci. U.S.A.* 98:8024-8029.

(2001) Le Buanec H., Vetu C., Lachgar A., Benoît M.-A., Gillard J., Paturance S., Aucouturier J., Gane V., Zagury D. & B. Bizzini: Induction in mice of anti-Tat mucosal immunity by the intranasal and oral routes. *Biomed. & Pharmacother.* 55:316-320.

(2001) Hendel H., Winkler C., Nelson G., Haumont P., O'Brien S., Khalili K., Zagury D., Rappaport J., J.F. Zagury: Validation of genetic case-control studies in AIDS and application to the CX3CR1 polymorphism. *JAIDS* 26:507-511.

(2001) D'Anna R., Le Buanec H., Bizzini B., Burny A., Giannouli C., Zagury J.F., Gallo R.C., Zagury D. & P. D'Alessio: Human papillomavirus-16-E7 oncoprotein enhances the expression of adhesion molecules in cervical endothelial cells but not in human umbilical vein endothelial cells. *J. Human Virol.* 4:85-95.

(2001) D'Anna R., Le Buanec H., Alessandri G., Caruso A., Burny A., Gallo R., Zagury J.F., Zagury D. & P. D'Alessio: Selective activation of cervical microvascular endothelial cells by human papillomavirus-16-E7 oncoprotein. *Journal of the National Cancer Institute* 93:1843-1851.

(2001) Capini C.J., Richardson, M.W., Sverstiuk A.E., Mirchandani J., Regulier E.G., Khalili K., Zagury J.F., & J. Rappaport: Auto-antibodies to TNF α in HIV infection: prospects for anti-cytokine vaccine therapy. *Biomed. & Pharmacother.* 55: 1-9.

- (2000) Richardson M.W., Sverstiuk A., Hendel H., Cheung T.W., Zagury J.F., J. Rappaport: Analysis of telomere length and thymic output in fast and slow/non-progressors with HIV infection. *Biomed. & Pharmacother.* 54:21-31.
- (2000) Pauza D., Trivedi P., Wallace M., Ruckwardt T.J., Le Buanec H., Lu W., Bizzini B., Burny A., Zagury D. & R.C. Gallo: Vaccination with Tat toxoid attenuates disease in simian/HIV-challenged macaques. *Proc. Natl. Acad. Sci. U.S.A.* 97:3515-3519.
- (2000) Le Buanec H. & B. Bizzini: Procedures for preparing biologically inactive, but immunogenic HIV-1 Tat protein (Tat Toxoid) for human use. *Biomed. & Pharmacother.* 54:41-44.
- (1999) Zagury D.: Tat toxoid, a component for preventive therapeutic AIDS vaccine: safety and immunogenicity. Quatrième Colloque des Cent Gardes 89-92.
- (1999) Zagury D., Lecoq H., Gervi I., Le Buanec H., Zagury J.F., Bizzini B., Burny A., Hermans P., Muça-Perja M., Santagostino E. & A. Gringeri: Anti-IFN α immunization raises the IFN α -neutralizing capacity of serum – an adjuvant to antiretroviral tritherapy. *Biomed. & Pharmacother.* 53:90-92.
- (1999) Le Buanec H., Lachgar A., D'Anna R., Zagury J.F., Bizzini B., Bernard J., Ittelé D., Hallez S., Giannouli C., Burny A. & D. Zagury: Induction of cellular immunosuppression by the human papillomavirus type 16E7 oncogenic protein. *Biomed. & Pharmacother.* 53:323-328.
- (1999) Le Buanec H., D'Anna R., Lachgar A., Zagury J.F., Bernard J., Ittelé D., D'Alessio P., Hallez S., Giannouli C., Burny A., Bizzini B., Gallo R.C. & D. Zagury: PV-16 E7 but not E6 oncogenic protein triggers both cellular immunosuppression and angiogenic processes. *Biomed. & Pharmacother.* 53:424-431.
- (1999) Lachgar A., Sojic N., Arbault S., Bruce D., Sarasin A., Amarote C., Bizzini B., Zagury D. & M. Vuillaume: Amplification of the inflammatory cellular redox state by HIV-1-immunosuppressive Tat and gp160 proteins. *J. Virol.* 73:1447-1452.
- (1999) Lachgar A., Le Buanec H., Burny A., Bizzini B. & D. Zagury: Lectine production by human T-lymphocytes. *Biomed. & Pharmacother.* 53:288-289.
- (1999) Hendel H., Caillat-Zucman S., Le Buanec H., Carrington M., O'Brien S.O., Andrieu J.M., Schächter F., Zagury D., Rappaport J., Winkler C., Nelson G. & J.F. Zagury: New class I and II HLA alleles strongly associated with opposite patterns of progression to AIDS. *J. Immunol.* 162:6942-6946.
- (1999) Gringeri A., Santagostino E., Muça-Perja M., Le Buanec H., Bizzini B., Lachgar A., Zagury J.F., Rappaport J., Burny A., Gallo R.C. & D. Zagury: Tat-Toxoid, as a component of a preventive vaccine in seronegative subjects. *JAIDS* 20:371-375.
- (1999) Gringeri A., Musicco M., Hermans P., Bentwich Z., Cusini M., Bergamasco A., Santagostino E., Burny A., Bizzini B., Zagury D. and the EURIS Study group: Active anti-

interferon- α immunization: A European-Israeli randomized, double-blind, placebo-controlled clinical trial in 242 HIV-1-infected patients (the EURIS Study). *JAIDS* 20:358-370.

(1999) Bizzini B., Volpato I., Lachgar A., Cohen P. & A. Gringeri: IFN α kinoid vaccine in conjunction with tritherapy, a weapon to combat immunopathogenesis in AIDS. *Biomed. & Pharmacother.* 53:87-89.

(1998) Zagury J.F., Sill A., Blattner W., Lachgar A., Le Buanec H., Richardson M., Rappaport J., Hendel H., Bizzini B., Gringeri A., Carcagno M., Criscuolo M., Burny A., Gallo R.C. & D. Zagury: Antibodies to the HIV-1 Tat protein correlated with nonprogression to AIDS: A rationale for the use of Tat toxoid as an HIV-1 vaccine. *J. Hum. Virol.* 1:282-292.

(1998) Zagury D., Lachgar A., Chams V., Fall L.S., Bernard J., Zagury J.F., Bizzini B., Gringeri A., Santagostino E., Rappaport J., Feldman M., O'Brian S.J., Burny A. & R.C. Gallo: C-C chemokines, pivotal in protection against HIV type 1 infection. *Proc. Natl. Acad. Sci. U.S.A.* 95:3857-3861.

(1998) Zagury D., Lachgar A., Chams V., Fall L.S., Bernard J., Zagury J.F., Bizzini B., Gringeri A., Santagostino E., Rappaport J., Feldman M., Burny A. & R.C. Gallo: Interferon α and Tat involvement in the immunosuppression of uninfected T cells and C-C chemokine decline in AIDS. *Proc. Natl. Acad. Sci. U.S.A.* 95:3851-3856.

(1998) Le Buanec H., Lachgar A., Bizzini B., Zagury J.F., Rappaport J., Santagostino E., Muça-Perja M. & A Gringeri: A prophylactic and therapeutic AIDS vaccine containing as a component the innocuous Tat Toxoid. *Biomed. & Pharmacother.* 52:431-435.

(1998) Lachgar A., Jaureguiberry G., Le Buanec H., Bizzini B., Zagury J.F., Rappaport J. & D. Zagury: Binding of HIV-1 to RBCs involves the Duffy antigen receptors for chemokines (DARC). *Biomed. & Pharmacother.* 52:436-439.

(1998) Hendel H., Henon N., Le Buanec H., Lachgar A., Poncelet H., Caillat-Zucman S., Winkler C., Smith M.W., Kenefic L., O'Brien S.O., Lu W., Andrieu J.M., Zagury D., Schächter F., Rappaport J. & J.F. Zagury: Distinctive effects of CCR5, CCR2 and SDF1 genetic polymorphisms on AIDS progression. *JAIDS* 19:381-386.

(1998) Gringeri A., Santagostino E., Muça-Perja M., Mannucci P.M., Zagury J.F., Bizzini B., Lachgar A., Carcagno M., Rappaport J., Criscuolo M., Blattner W., Burny A., Gallo R.C. & D. Zagury: Safety and immunogenicity of HIV-1 Tat Toxoid in immunocompromised HIV-1-infected patients. *J. Hum. Viro.* 1:293-298.

(1998) Achour A., Landureau J.C., Salerno-Concalves R., Mazière J.C. & D. Zagury: Restoration of immune response by a cationic amphiphilic drug (AY 9944) in vitro: A new approach to chemotherapy against human immunodeficiency virus type 1. *Antimicrobial Agents and Chemotherapy* 42:2482-2491.

(1997) Zagury D.: A naturally unbalanced combat. *Nature Medicine* 3 n°2:156-157.

(1997) Rappaport J, Cho Y.Y., Hendel H., Swartz E., Schächter F. & J.F. Zagury: 32 bp CCR-5 gene deletion and resistance to fast progression in HIV-1 infected heterozygotes. *The Lancet* 349:922.

- (1997) Coulaud J.P., Gougeon M.L., Gomard E., Descamps D., Lebon P., Aboulker J.P., Bizzini B. & D. Zagury: A placebo-controlled clinical Phase I trial with combined anti-HIV and anti-interferon α immunization. *AIDS* 11:937-938.
- (1997) Achour A., Lachgar A., Astgen A., Chams V., Bizzini B., Tapiero H., & D. Zagury: Potentialization of IL-2 effects on immune cells by oyster extract (JCOE) in normal and HIV-infected individuals. *Biomed. & Pharmacother.* 51:427-429.
- (1997) Cho Y.Y., Astgen A., Hendel H., Issing W., Perrot J.Y., Schächter F., Rappaport & J.F. Zagury: Homeostasis of chemokines, interferon production and lymphocyte subsets: implications for AIDS pathogenesis. *Biomed. & Pharmacother.* 51:221-229.
- (1996) Zagury J.F., Chams V., Lachgar, Carcagno M., Rappaport J., Bizzini B. & A. Burny: Model of AIDS immunopathogenesis based on the HIV-1 gp120 and Tat-induced dysregulation of uninfected immune cells. *Cellular Pharmacology-AIDS Sciences* 3:281-286.
- (1996) Moukrim Z., Cho Y.Y., M'Bika J.P. & A. Achour: Lymphoproliferative response to synthetic V3 loop P18 peptide and HIV-1 envelope glycoprotein among individuals immunized with gp160 candidate vaccines. *Biomed. & Pharmacother.* 50:494-499.
- (1996) Lachgar A., Bernard J., Bizzini B., Astgen A., Le Coq H., Fouchard M., Chams V., Feldman M., Richardson M., Rappaport J., Burny A. & J.F. Zagury: Repair of the in vitro HIV-1-induced immunosuppression and blockade of the generation of functional suppressive CD8 cells by anti-alpha interferon and anti-Tat antibodies. *Biomed. & Pharmacother.* 50:13-18.
- (1996) Hendel H., Cho Y.Y., Gaultier N., Rappaport J., Schächter F. & J.F. Zagury: Contribution of cohort studies in understanding HIV pathogenesis: introduction of the GRIV cohort and preliminary results. *Biomed. & Pharmacother.* 50:480-487.
- (1996) Achour A., Bex F., Hermans P., Burny A. & D. Zagury: Induction of anti-gp160 cytotoxic T cell cross-reacting with various V3 loop P18 peptides in human immunodeficiency virus type 1 envelope-immunized individuals. *J. Virol.* 70:6741-6750.
- (1996) 79 - Zagury D., Lachgar A., Bernard J., Bizzini B., Astgen A., Le Coq H., Fouchard M., Chams V., Feldman M., Richardson M., Rappaport J., Burny A., Zagury J.F. & R.C. Gallo: A critical role of Tat and IFN α in the HIV-1-induced immunosuppression leading to AIDS. *Cellular Pharmacology-AIDS Sciences* 3:97-103.
- (1995) Zagury D., Bizzini B. & A. Burny: Editorial, *Cellular and Molecular Biology* 41:I.
- (1995) Moukrim Z. & A. Achour A.: Cytotoxic T lymphocytes specific for the synthetic VEINCTR peptide, a sequence found within the Fas molecule and *env* gp120 in the blood of HIV-1 seropositive individuals. *Cellular and Molecular Biology* 41:439-444.
- (1995) Landureau J.C., Achour A., Fouchard M., M'Bika J.P., Mazière J.C. & D. Zagury: Which nutrient supplements for optimal HIV-1 production by cultured human lymphocytes? *Cellular and Molecular Biology* 41:423-430.

- (1995) Lachgar A. & B. B. Bizzini: Contribution of alpha (α IFN) to HIV-induced immunosuppression. *Cellular and Molecular Biology* 41:431-437.
- (1995) Gringeri A., Santagostino E., Siracusano L., Marinoni A., Criscuolo M., Carcagno M., Fall L.-S., M'Bika J.P., Bizzini B. & D. Zagury: Anti-alpha interferon immunization: safety and immunogenicity in asymptomatic HIV positive patients at high risk of disease progression. *Cellular and Molecular Biology* 41:381-387.
- (1995) Gringeri A., Santagostino E., Cusini M., Muça-Perja M., Marinoni A., Mannucci P.M., Burny A., Criscuolo M., Lu W., Andrieux J.M. M'Bika J.P., Lachgar A., Fall L.S., Chams V., Feldman M., Hermans P., Zagury J.F., Bizzini B. & D. Zagury: Absence of clinical, Virological and immunological signs of progression in HIV-1-infected patients receiving active anti-alpha interferon immunization: a 30 month follow-up report. *JAIDS* 13:55-67.
- (1995) Fall L.-S., Chams V., Le Coq H., Fouchard M., M'Bika J. P., Gringeri A., Santagostino E. & B. Bizzini: Evidence for an antiviral effect and interferon neutralizing capacity in human sera; Variability and implications for HIV infection. *Cellular and Molecular Biology* 41:409-416.
- (1995) Cantalloube H., Labesse G., Chomilier J., Nahum C., Cho Y. Y., Chams V., Achour A., Lachgar A., M'bika J. P., Issing W., Mornon J. P., Bizzini B., Zagury D. & J.F. Zagury: Automat and BLAST : comparison of two protein sequence similarity search programs. *CABIOS* 11:261-272.
- (1995) Bizzini B. & A. Achour "Kinoids": The basis for anticytokine immunization and their use in HIV infection. *Cellular and Molecular Biology* 41:351-356.
- (1995) Achour A., Moukrim Z., Picard O., Bizzini B., Burny A. & D. Zagury: HIV-soluble antigens induced CD8⁺ cytotoxic T-cell responses in an immunized individual. *Cellular and Molecular Biology* 41:395-400.
- (1995) Achour A., Bizzini B., Burny A., Zagury D; & J.F. Zagury: A CD4 pentapeptide as an in vitro target for specific CTLs in HIV-1-infected individuals. *Immunology & Infectious Diseases* 5:270-276.
- (1995) Zagury J.F., Chams V., Zagury D., Lachgar A., Bizzini B., Burny A. & M. Feldman: Are CD4 and Fas peptide identities of gp120 relevant to the molecular basis of AIDS pathogenesis? *Cell Death & Differentiation* 2:23-32.
- (1994) Zagury J.F., Lachgar A., Achour A., Chams-Harvey V., Cho Y.Y., Le Coq H., Bizzini B., Feldman M., Burny A. & D. Zagury: Pathogenic disorders involved in immunosuppression and T cell depletion characterizing AIDS. *Biomed. & Pharmacother.* 48:11-16.
- (1994) Mazière J.-C., Landureau J.-C., Giral P., Auclair M., Fall L., Lachgar A., Achour A; and Zagury D. Lovastatin inhibits HIV-1 expression in H9 human T lymphocytes cultured in cholesterol-poor medium. *Biomed. & Pharmacother.* 48:63-67.

- (1994) Lachgar A. & B. Bizzini Involvement of α -interferon in HIV-1 induced immunosuppression. A potential target for AIDS prophylaxis and treatment. *Biomed. & Pharmacother.* 48:73-77.
- (1994) Gringeri A., Santagostino E., Mannucci P.M., Tradati F., Cultraro D., Buzzi A., Criscuolo M., David A., Guillemot L., Barré-Sinoussi F., Lachgar A., Chams V., Le Coq H., Fouchard M., Achour A., Fall L., Defer M.C., Picard O., Hermans P., Burny A., Feldman M., Chany C., Zagury J.F., Bizzini B. & D. Zagury: A randomized, placebo-controlled, blind anti-AIDS clinical trial: safety and immunogenicity of a specific anti-IFN α immunization. *JAIDS* 7:978-988.
- (1994) Fall L.S., M'Bika J.P., Le Coq H., Fouchard M., Astgen A., Bizzini B., Gringeri A., Santagostino E., Burny A., Zagury D. & V. Chams: Biological effect of active anti-IFN α immunization in HIV-infected patients. *Biomed. & Pharmacother.* 49:422-428.
- (1994) Chams V., Biou D., Cho Y. Y., M'Bika J.P., Le Coq H., Heshmati F., Fouchard L., Bizzini B. & J.F. Zagury: Effect of purified IgGs from HIV-1 infected and non infected individuals on immune activation. *Biomed. & Pharmacother.* 48:267-272.
- (1994) Cantalloube H., Nahum C., Achour A., Lehner T., Callebaut I., Burny A., Bizzini B., Mornon J-P., Zagury D. & J.F. Zagury: Automat: a novel software system for the systematic search for protein (or DNA) similarities with a notable application to autoimmune diseases and AIDS. *Computer application to biological sciences* 10:153-161.
- (1994) Cantalloube H. M. J., Nahum C. E. & J.F. Zagury: Screening of protein sequences databanks by Automat for search of host sequences integration and/or autoimmune disorders induction by retroviruses. *Biomed. & Pharmacother.* 48:17-26.
- (1994) Bex F., Hermans P., Sprecher S., Achour A., Badjou R., Desgranges C., Cogniaux J., Franchioli P., Vanhulle C., Lachgar A., Stryckmans P., Zagury D., Burny A. & N. Clumeck: Syngeneic adoptive transfer of anti-human immunodeficiency virus-1 (HIV-1)-primed lymphocytes from a vaccinated HIV-seronegative individual to his HIV-1-infected identical twin. *Blood* 84:3317-3326.
- (1994) Achour A., Moukrim Z., Zagury J.F. , Picard O., Bruny A. & D. Zagury: Detection of CTL activity in PBMCs taken from HIV-ENV immunized individuals after *in vitro* viral infection. *Biomed. & Pharmacother.* 48:7-10.
- (1994) Achour A., Lemhammedi S., Picard O., M'Bika J.P., Zagury J.F., Moukrim Z., Willer A., Beix F., Burny, A., & D. Zagury: Cytotoxic T lymphocytes specific for HIV-1 gp160 antigen and synthetic P18IIIB peptide in an HLA-A11-immunized individual. *AIDS Res. & Human Retroviruses* 10:19-25.
- (1993) Zagury J.F., Cantalloube H., Achour A., Cho Y.Y., Fall L., Lachgar A., Chams V., Astgen A., Biou D., Picard O., Callebaut I., Mornon J.P., Burny A., Feldman M., Bernard J., Bizzini B. & D. Zagury: Striking similarities between HIV-1 Env protein and the apoptosis mediating cell surface antigen Fas. Role in AIDS pathogenesis. *Biomed. & Pharmacother.* 47:331-335.

(1993) Zagury J.F., Bernard J., Achour A., Astgen A., Lachgar A., Fall L., Carelli C., Issing W., Mbika J.P., Picard O., Carlotti M., Callebaut I., Mornon J.P., Burny A., Feldman M., Bizzini B. & D. Zagury: Identification of CD4 and major histocompatibility complex functional peptide sites and their homology with oligopeptides from human immunodeficiency virus type 1 glycoprotein gp120 : Role in AIDS pathogenesis. *Proc. Natl. Acad. Sci. USA* 90:7573-7577.

(1993) Zagury J.F., Bernard J., Achour A., Astgen A., Lachgar A. Fall L., Carelli C., Issing I., Mbika J.P., Cantalloube H., Picard O., Gourbil A., Guignon J.M., Cozette J., Faure J.P., Biou D., Carlotti M., Callebaut I., Mornon J.P., Burny A., Feldman M., Bizzini B. & D. Zagury: HIV-1-induced immune suppression may result from autoimmune disorders including anti-SLWDQ autoantibodies. *Biomed. & Pharmacother.* 47:93-99.

(1993) Zagury D., Bizzini B., Bernard J., Feldman M., Burny A. & J.F. Zagury: Model of AIDS pathogenesis. Abstract of the presentation by D. Zagury at the *LTCB Annual Meeting, JAIDS*, *supp.*, 6:680.

(1993) Zagury D., Bernard J., Halbreich A., Bizzini B., Carelli C., Achour A., Defer M.C., Bertho J.M., Lanneval K., Zagury J.F., Salaun J.J., Lurhuma Z., Mbayo K., Aboud-Pirak E., Lowell G., Lebon P., Burny A. & O. Picard: One-year follow-up of vaccine therapy in HIV-infected immune-deficient individuals: new strategy. *Infectious Diseases Digest* n°3:22-23.

(1993) Kolesnitchenko V., Agius G., Zagury J.F., Laaroubi K., Achour A., Castets & D. Zagury: Polymerase chain reaction amplified HTLV-1, HIV-1 and HIV-2 DNA fragments in subjects with mixed retroviral infections. *J. Med. Microbiol.* 38:309-388.

(1993) Bex F., Becker N., Collette Y., Deschamps M., Gonzales S., Hermans P., Lambrecht B., Van de Perre P., Vanhulle C., Zagury J.F., Zagury D., Clumeck N. & A. Burny: Vaccination against AIDS: Facts, problems and hopes for success. in *AIDS-SIDA, A comparison between Europe and Africa*, Editions Roche p. 21-32.

(1993) Achour A., Picard O., Mbika J.P., Willer A., Snart R., Bizzini B., Carelli C., Burny A. & D. Zagury: Envelope protein and p18(IIIB) peptide recognized by cytotoxic T lymphocytes from humans immunized with human immunodeficiency virus envelope. *Vaccine* 11:699-701.

(1992) Zagury J.F., Cantalloube H., Bernard J., Lachgar A., Fall L., Achour A., Mbika J.P., Cosme M.H., Pellion F., Issing W., Carelli C., Bizzini B., Thoreau E., Callebaut I., Burny A., Mornon J.P. & Zagury D.: Critical sites: a semantic approach to protein sequences. Application to the HIV-1 envelope molecule. *Biomed. & Pharmacother.* 46:343-351.

(1992) Zagury D., Bernard J., Halbreich A., Bizzini B., Carelli C., Achour A., Defer M.C., Bertho J.M., Lanneval K., Zagury J.F., Salaun J.J., Lurhuma Z., Mbayo K., Aboud-Pirak E., Lowell G., Lebon P., Burny A. & O. Picard: One-year follow-up of vaccine therapy in HIV-infected immune-deficient individuals: a new strategy. *JAIDS* 5:676-681.

(1992) Willer A., Achour A., Mbika J.P., Laaroubi K., Lachgar A., Nihrane A., Picard O., Naylor P.H., Sarin P.S., Goldstein A.L. & D. Zagury: Cell-mediated immunity against HGP-30, a group-specific peptide of HIV p17 in individuals infected with the AIDS virus. *Biomed. & Pharmacoter.* 46:359-365.

- (1992) Picard O., Bernard J., Lachgar A., Fall L., Carlotti M., Achour A., Carelli C., Salaun J.J., Mbika J.P., Lurhuma Z., Desgranges C., Boyer V., Burny A., Zagury J.F., Bizzini B. & D. Zagury: Removal of gp160 induced deleterious effects for a safe AIDS vaccine candidate. *Biomed. & Pharmacother.* 46:353-357.
- (1992) Picard O., Achour A., Bernard J., Halbreich A., Bizzini B., Boyer V., Desgranges C., Bertho J.M., Lachgar A., Polliotti B., Defer M.C., Lanneval K., Imbert J.C., Frottier J., Salaun J.J., Burny A. & D. Zagury: A 2-year follow-up of an anti-HIV immune reaction in HIV-1 gp160-immunized healthy seronegative humans: evidence for persistent cell-mediated immunity. *JAIDS* 5:539-546.
- (1992) Halbreich A., Lachgar A., Bertho J.M., Lanneval K., Nihrane A., Achour A., Polliotti B., Bernard J., Carelli C., Picard O., Bizzini B., Burny A. & D. Zagury: RNA-free HIV-1 particles (hivions): biochemical preparation and immunobiological properties. *Vaccine Research* 1:397-411.
- (1992) Carelli C., Halbreich A., Bernard J., Bizzini B., Achour A., Zagury J.F., Lebon P., Polliotti B., Folghera S., Laaroubi K., Aboud-Pirak E., Lowell G., Burny A., Picard O. & D. Zagury: Immunogenicity of combined anti-HIV and anti-suppressive vaccine preparations. *Biomed. & Pharmacother.* 46:149-153.
- (1992) Gazzard B., Youle M., MacDonald V., O'Toole C.M., Stambuk D., Rios A., Achour A., Zagury D., Naylor P.H., Sarin P.S. & A.L. Goldstein: Safety and immunogenicity of HGP-30: evaluation of a synthetic HIV-1 p17 vaccine in healthy HIV-seronegative volunteers. *Vaccine Research* 1:129-135.
- (1992) Zagury J.F., Cantalloube H., Bernard J., Mornon J.P., Bizzini B. & D. Zagury: Striking identity between HIV-1 envelope glycoprotein gp120 and its CD4 receptor. *The Lancet* 340:483-484.
- (1991) Zagury D.: Anti-HIV cellular immunotherapy in AIDS. *The Lancet* 338:694-695.
- (1991) Picard O., Lebas J., Imbert J.C., Bigel P. & D. Zagury: Complication of intramuscular/subcutaneous immune therapy in severely immune-compromised individuals. *JAIDS* 4:641-643.
- (1991) Naylor P.H., Szein M. B., Wada S., Maurer S., Holterman D., Kirkley J.E., Naylor C.W., Zook B.C., Hitzelberg R.A., Gibbs Jr C.J., Zagury D., Achour A., O'Toole C., Gazzard B., Youle M., Rios A., Sarin P.S. & A.L. Goldstein: Preclinical and clinical studies on immunogenicity and safety of the HIV-1 p17-based synthetic peptide AIDS Vaccine - HGP-30-KLH. *Int. J. Immunopharmac.* 13 Suppl 1:117-127.
- (1991) Faure P., Achour A. & Zagury D.: HGP30, peptide intéressant dans une perspective vaccinale contre le VIH-1 (virus d'immunodéficience humaine), agent du Sida. *Immunoanal. Biol. Spec.* 25:9-16.
- (1991) Boyer V., Broly H., Souche S., Madaule P., Rossier J., Zagury D. & C. Desgranges: Characterization and large production of human monoclonal antibodies against the HIV-1 envelope. *Clin. Exp. Immunol.* 83:452-459.

- (1990) Zagury J.F., Josephs S.F., Agius G., Nicol I., Willer A., Kalyanaraman V.S., Zagury D., Wong-Staal F. & R.C. Gallo: In vitro characterization of a biologically active molecular clone of HIV-2_{NIH-Z} containing a *nef* deletion and expressing a full-length transmembrane protein. *AIDS Res. and Hum. Retrovir.* 6:1079-1085.
- (1990) Picard O., Giral P., Defer M.C., Fouchard M., Morel M., Meyohas M.C., Lebas J., Imbert J.C., Frottier J., Salaun J.J., Lurhuma Z., Moss B., Gallo R.C. & D. Zagury: Aids vaccine therapy: phase 1 trial. *The Lancet* 336 n° 8708:179.
- (1990) Bernard J., Réveil B., Najman I., Liautaud-Roger F., Fouchard M., Picard O., Cattan A., Mabondzo A., Laverne S., Gallo R.C. & D. Zagury: Discrimination between protective and enhancing HIV antibodies. *AIDS Res. and Hum. Retrovir.* 6:243-249.
- (1990) Bernard J., Reveil B., Najman I., Liautaud-Roger F., Fouchard M., Picard O., Cattan A., Mabondzo A., Laverne S., Gallo R.C. & D. Zagury: Discrimination between protective and enhancing HIV antibodies. *AIDS Res. and Hum. Retrovir.* 6:243-249.
- (1990) Agius G., Kolesnitchenko V., Snart R., Zagury J.F., Laaroubi K. & D. Zagury: Variable stringency hybridization of polymerase chain reaction amplified HIV-1 DNA fragments. *Journal of Virological Methods* 30:141-150.
- (1990) Agius G., Desportes I., Flamminio-Zola G. & Zagury D., Lurhuma Z., Salaun J.J. & R.C. Gallo: HIV-1 infection in Central Africa. Some epidemiologic and prevention aspects. In: *AIDS Vaccine Research and Clinical Trials* chapt. 21:409-423.
- (1990) Achour A., Picard O., Zagury D., Sarin P.S., Gallo R.C., Naylor P.H. & A.L. Goldstein: HGP-30, a synthetic analogue of human immunodeficiency virus (HIV) p17, is a target for cytotoxic lymphocytes in HIV-infected individuals. *Proc. Natl. Acad. Sci. U.S.A.* 87:7045-7049.
- (1989) Picard O., Imbert J.C., Lurhuma Z., Salaun J.J., Moss B., Gallo R.C. & D. Zagury: Immune therapy: clinical trial (phase 1) in AIDS/ARCS patients. *Quatrième Colloque des Cent Gardes* 319-322.
- (1989) Nicol I., Messinger D., Dubouch P., Bernard J., Desportes I., Jouffre R., Snart R., Nara P., Gallo R.C. & D. Zagury: Use of Old World monkeys for acquired immunodeficiency syndrome research. *J. Med. Primatol.* 18:227-236.
- (1989) Nicol I., Flamminio-Zola G., Dubouch P., Bernard J., Snart R., Jouffre R., Reveil B., Fouchard M., Desportes I., Nara P., Gallo R.C. & D. Zagury: Persistent HIV-2 infection of rhesus macaque, baboon and mangabeys. *Intervirology* 30:258-267.
- (1989) Desportes I., Bonnet D., Nicol I., Snart R. & P.S. Sarin: Expression of HIV antigens at the surface of infected T4 cells: immunoelectron microscopic evidence of an immunogenic phase prior to the viral release. *AIDS Res. and Hum. Retrovir.* 5:107-113.
- (1988) Berzofsky J.A., Bensussan A., Cease K.B., Bourge J.F., Cheynier R., Lurhuma Z., Salaun J.J., Gallo R.C., Shearer G.M. & D. Zagury: Antigenic peptides recognized by T lymphocytes from AIDS viral envelope-immune humans. *Nature* 334:706-708.

(1988) Zagury D., Bernard J., Cheynier R., Desportes I., Leonard R., Fouchard M., Reveil B., Ittele D., Lurhuma Z., Mbayo K., Wane J., Salaun J.J., Goussard B., Dechazal L., Burny A., Nara P. & R.C. Gallo: A group specific anamnestic immune reaction against HIV-1 induced by a candidate vaccine against AIDS. *Nature* 332 n°6166:728-731.

(1988) Zagury J.F., Franchini G., Reitz M., Collalti E., Starcich B., Hall L., Fargnoli K., Jagodzinski L., Guo H.G., Laure F., Arya S.K., Josephs S., Zagury D., Wong-Staal F. & R.C. Gallo: Genetic variability between isolates of human immunodeficiency virus (HIV) type 2 is comparable to the variability among HIV type 1. *Proc. Natl. Acad. Sci. U.S.A.* 85:5941-5945.

(1988) Zagury D., Salaun J.J., Bernard J., Dechazal L., Goussard B. & Z. Lurhuma: Immunisation contre le virus de l'immunodéficience humaine au Zaïre. *Médecine Tropicale* 48:417-423.

(1988) Zagury D. & Z. Lurhuma: AIDS control in Africa. *Eds De Vitta et Rosenberg AIDS* Chapt 27:431-445.

(1988) Yourno J., Josephs S.F., Reitz M., Zagury D., Wong-Staal F. & Gallo R.C.: Nucleotide sequence analysis of the *env* gene of a new Zairian isolate of HIV-1. *AIDS Res. and Hum. Retrovir.* 4:165-173.

(1988) Van den Broeke A., Cleuter Y., Chen G., Portetelle D., Mammerickx M., Zagury D., Fouchard M., Coulombel L., Kettmann R. & A. Burny: Even transcriptionally competent proviruses are silent in bovine leukemia virus-induced sheep tumor cells. *Proc. Natl. Acad. Sci. U.S.A* 85:9263-9267.

(1988) Thiriart C., Goudsmit J., Schellekens P., Barin F., Zagury D., De Wilde M. & C. Bruck: Antibodies to soluble CD4 in HIV-1 infected individuals. *AIDS* 2:345-351.

(1988) Léonard R., Zagury D., Desportes I., Bernard J., Zagury J.F. & R.C. Gallo: Cytopathic effect of human immunodeficiency virus in T4 cells is linked to the last stage of virus infection. *Proc. Natl. Acad. Sci. U.S.A.* 85:3570-3574.

(1988) Desgranges C., Boyer V., Souche S., Sprecher S., Burny A., Gallo R.C., Bernard J., Reveil B. & D. Zagury: Monoclonal antibodies to HIV in a non-infected, immunised volunteer. *The Lancet* 23:935-936.

(1988) Cheynier R., Soulha M., Lauré F., Vol J.C., Reveil B., Gallo R.C., Sarin P.S. & D. Zagury: HIV-1 expression by T8 lymphocytes after transfection. *AIDS Res. and Hum. Retrovir.* 4:43-50.

(1987) Zagury D., Léonard R., Fouchard M., Reveil B., Bernard J., Ittele D., Cattan A., Lurhuma Z., Mbayo K., Wane J., Salaun J.J. & B. Goussard: Immunization against AIDS in humans. *Nature* 326:249-250.

(1987) Lauré F., Léonard R., Mbayo K., Lurhuma Z., Kayembe N., Brechot C., Sarin P.S., Sarngadharan M., Wong-Staal F., Gallo R.C. & D. Zagury: Genomic diversity of Zairian HIV isolates: biological characteristics and clinical manifestation of HIV infection. *AIDS Res. and Hum. Retrovir.* 3:343-353.

(1987) Kanki P.J., Allan J., Barin F., Redfield R., Clumeck N., Quinn T., Mowovondi F., Thiry L., Burny A., Zagury D., Petat E., Kocheleff P., Kadende P., Lausen I., Fredericksen B., Craighead J., M'Boup S., Denis F., Curran J.W., Mann J., Francis H., Albaum M., Travers K., McLane M.F., Lee T.H. & M. Essex: Absence of antibodies to HIV-2/HTLV-4 in six central African nations. *AIDS Res. and Hum. Retrovir.* 3:317-322.

(1986) Zagury D., Bernard J., Leonard R., Cheynier R., Feldman M., Sarin P.S. & R.C. Gallo: Long-term cultures of HTLV-III-infected T cells: a model of cytopathology of T-cell depletion in AIDS. *Science* 231:850-853.

(1986) Fouchard M., Reveil B., Mbayo K., Lurhuma A., Sarin P.S., Gallo R.C. & D. Zagury: Evidence for HTLV-III/LAV expression by primary cultures of T8 cells. *Int. J. Cancer* 38:657-659.

(1985) Zagury D., Fouchard M., Vol J.C., Cattan A., Leibowitch J., Feldman M., Sarin P.S. & R.C. Gallo: Detection of infectious HTLV-III/LAV virus in cell-free plasma from AIDS patients. *The Lancet* 2:505-506.

(1985) Zagury D., Gagne I., Reveil B., Bernard J., Zagury J.F., Saimot A.G., Sarin P.S. & R.C. Gallo: Repairing the T cell defects in AIDS. *The Lancet* 2:449.

(1985) Zagury D., Fouchard M., Cheynier R., Bernard J., Cattan A., Zaki Salahuddin S. & P.S. Sarin: Evidence for HTLV-III in T-Cells from semen of AIDS patients: expression in primary cell culture, long-term mitogen-stimulated cell cultures and cocultures with a permissive T-Cell line. *Cancer Research* 45:4595-4597.

(1985) Laure F., Zagury D., Saimot A.G., Gallo R.C., Hahn B.H. & C. Bréchet: Hepatitis B virus DNA sequences in lymphoid cells from patients with AIDS and AIDS-related complex. *Science* 229:561-563.

(1984) Zagury D., Bernard J., Leibowitch J., Safai B., Groopman J.E., Feldman M., Sarngadharan M.G. & R.C. Gallo: HTLV-III in cells cultured from semen of two patients with AIDS. *Science* 226:449-451.